Invitrogen Contributes New Research for ALS

Invitrogen’s stem cell business is participating in a new research program designed to find treatments for ALS. Life Technologies, Invitrogen’s parent company, has partnered with the University of California San Diego and the Salk Institute for Biological Studies to research cell transplant therapies as a potential ALS treatment.

Click here to read more.

Share this: